Characteristics of human umbilical cord mesenchymal stem cells during ex vivo expansion

Li,Shengying; Wang,Yuxia; Guan,Liping; Ji,Mingli

doi:10.3892/mmr.2015.3999

Characteristics of human umbilical cord mesenchymal stem cells during ex vivo expansion

Authors:
- Shengying Li
- Yuxia Wang
- Liping Guan
- Mingli Ji
View Affiliations

Affiliations: Department of Pharmacology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Pathophysiology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Functional Science Laboratory, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Physiology, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
Published online on: June 25, 2015 https://doi.org/10.3892/mmr.2015.3999
Pages: 4320-4325

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human umbilical cord mesenchymal stem cells (hUCMSCs) have potential clinical applications in different types of diseases. In order to acquire enough cells, hUCMSCs have to be expanded ex vivo. However, it remains to be elucidated whether the characteristics of hUCMSCs are altered during ex vivo expansion. In the present study, the quality of hUCMSCs, which is important for successful therapeutic use, was systematically examined during hUCMSC expansion ex vivo. Morphologically, hUCMSCs exhibited no visible changes during culture. In addition, hUCMSCs retained their proliferative ability between passages 0-5. At the molecular level, the cells continued expressing the specific positive surface markers, CD29, CD73 and CD90, and did not express the negative surface markers, CD14, CD34 or CD45, during culture ex vivo. Furthermore, the hUCMSCs exhibited low immunogenicity, which was maintained when cultured for five passages. However, the immunological properties of hUCMSCs were altered at passage 10, at which the percentage of hUCMSCs expressing human leukocyte antigen‑I was significantly increased. Collectively, these results suggested that hUCMSCs used for cell-based therapies require obtaining from cells, which have been expanded for fewer than five passages.

View Figures

View References

1	Beyer Nardi N and da Silva Meirelles L: Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol. 249–282. 2006. View Article : Google Scholar
2	Brighton CT and Hunt RM: Early histological and ultrastructural changes in medullary fracture callus. J Bone Joint Surg Am. 73:832–847. 1991.PubMed/NCBI
3	Brighton CT and Hunt RM: Early histologic and ultrastructural changes in microvessels of periosteal callus. J Orthop Trauma. 11:244–253. 1997. View Article : Google Scholar : PubMed/NCBI
4	Birbrair A, Wang ZM, Messi ML, Enikolopov GN and Delbono O: Nestin-GFP transgene reveals neural precursor cells in adult skeletal muscle. PLoS One. 6:e168162011. View Article : Google Scholar : PubMed/NCBI
5	Jiang Y, Jahagirdar BN, Reinhardt RL, et al: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:41–49. 2002. View Article : Google Scholar : PubMed/NCBI
6	Zhou C, Yang B, Tian Y, et al: Immunomodulatory effect of human umbilical cord Wharton's jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol. 272:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
7	Liu S, Yuan M, Hou K, et al: Immune characterization of mesenchymal stem cells in human umbilical cord Wharton's jelly and derived cartilage cells. Cell Immunol. 278:35–44. 2012. View Article : Google Scholar : PubMed/NCBI
8	Huang P, Lin LM, Wu XY, et al: Differentiation of human umbilical cord Wharton's jelly-derived mesenchymal stem cells into germ-like cells in vitro. J Cell Biochem. 109:747–754. 2010.PubMed/NCBI
9	Yang F, Yang D, Tu J, Zheng Q, Cai L and Wang L: Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating Wnt/catenin signaling. Stem Cells. 29:981–991. 2011. View Article : Google Scholar : PubMed/NCBI
10	Chao KC, Yang HT and Chen MW: Human umbilical cord mesenchymal stem cells suppress breast cancer tumourigenesis through direct cell-cell contact and internalization. J Cell Mol Med. 16:1803–1815. 2012. View Article : Google Scholar
11	Wang H, Qiu X, Ni P, et al: Immunological characteristics of human umbilical cord mesenchymal stem cells and the therapeutic effects of their transplantion on hyperglycemia in diabetic rats. Int J Mol Med. 33:263–270. 2014.
12	Le Blanc K: Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy. 5:485–489. 2003. View Article : Google Scholar : PubMed/NCBI
13	Nauta AJ and Fibbe WE: Immunomodulatory properties of mesenchymal stromal cells. Blood. 110:3499–3506. 2007. View Article : Google Scholar : PubMed/NCBI
14	Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. 2008. View Article : Google Scholar
15	Kon E, Muraglia A, Corsi A, et al: Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerate bone repair in critical-size defects of sheep long bones. J Biomed Mater Res. 49:328–337. 2000. View Article : Google Scholar
16	Solchaga LA, Temenoff JS, Gao J, Mikos AG, Caplan AI and Goldberg VM: Repair of osteochondral defects with hyaluronan- and polyester-based scaffolds. Osteoarthritis Cartilage. 13:297–309. 2005. View Article : Google Scholar : PubMed/NCBI
17	Amado LC, Saliaris AP, Schuleri KH, et al: Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci USA. 102:11474–11479. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lin YT, Chern Y, Shen CK, et al: Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PloS One. 6:e229242011. View Article : Google Scholar : PubMed/NCBI
19	Miyahara Y, Nagaya N, Kataoka M, et al: Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 12:459–465. 2006. View Article : Google Scholar : PubMed/NCBI
20	Di Nicola M, Carlo-Stella C, Magni M, et al: Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 99:3838–3843. 2002. View Article : Google Scholar : PubMed/NCBI
21	Le Blanc K, Frassoni F, Ball L, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 371:1579–1586. 2008. View Article : Google Scholar : PubMed/NCBI
22	Le Blanc K, Rasmusson I, Sundberg B, et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 363:1439–1441. 2004. View Article : Google Scholar : PubMed/NCBI
23	Mundra V, Gerling IC and Mahato RI: Mesenchymal stem cell-based therapy. Mol Pharm. 10:77–89. 2013. View Article : Google Scholar :
24	Friedenstein AJ, Gorskaja JF and Kulagina NN: Fibroblast precursors in normal and irradiated mouse hematopoietic organs. Exp Hematol. 4:267–274. 1976.PubMed/NCBI
25	Mennan C, Wright K, Bhattacharjee A, Balain B, Richardson J and Roberts S: Isolation and characterisation of mesenchymal stem cells from different regions of the human umbilical cord. Biomed Res Int. 2013:9161362013. View Article : Google Scholar : PubMed/NCBI
26	Roobrouck VD, Ulloa-Montoya F and Verfaillie CM: Self-renewal and differentiation capacity of young and aged stem cells. Exp Cell Res. 314:1937–1944. 2008. View Article : Google Scholar : PubMed/NCBI
27	Sarugaser R, Lickorish D, Baksh D, Hosseini MM and Davies JE: Human umbilical cord perivascular (HUCPV) cells: a source of mesenchymal progenitors. Stem Cells. 23:220–229. 2005. View Article : Google Scholar : PubMed/NCBI
28	Schellenberg A, Lin Q, Schuler H, et al: Replicative senescence of mesenchymal stem cells causes DNA-methylation changes which correlate with repressive histone marks. Aging. 3:873–888. 2011.PubMed/NCBI
29	Deuse T, Stubbendorff M, Tang-Quan K, et al: Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 20:655–667. 2011. View Article : Google Scholar
30	Baksh D, Yao R and Tuan RS: Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 25:1384–1392. 2007. View Article : Google Scholar : PubMed/NCBI
31	Weiss ML, Medicetty S, Bledsoe AR, et al: Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells. 24:781–792. 2006. View Article : Google Scholar
32	Fu YS, Cheng YC, Lin MY, et al: Conversion of human umbilical cord mesenchymal stem cells in Wharton's jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells. 24:115–124. 2006. View Article : Google Scholar
33	Lund RD, Wang S, Lu B, et al: Cells isolated from umbilical cord tissue rescue photoreceptors and visual functions in a rodent model of retinal disease. Stem Cells. 25:602–611. 2007. View Article : Google Scholar
34	Rachakatla RS, Marini F, Weiss ML, Tamura M and Troyer D: Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther. 14:828–835. 2007. View Article : Google Scholar : PubMed/NCBI
35	Cho PS, Messina DJ, Hirsh EL, et al: Immunogenicity of umbilical cord tissue derived cells. Blood. 111:430–438. 2008. View Article : Google Scholar
36	Wang S, Yu L, Sun M, et al: The therapeutic potential of umbilical cord mesenchymal stem cells in mice premature ovarian failure. Biomed Res Int. 2013:6904912013. View Article : Google Scholar : PubMed/NCBI
37	Karahuseyinoglu S, Cinar O, Kilic E, et al: Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells. 25:319–331. 2007. View Article : Google Scholar